Table 2.

Proposed severity threshold validation: simple kappa correlations of IGAxBSA vs. EASI and SCORAD for patients in randomized controlled trials^a

Validation statistic	Placebo (with or without TCS), n = 1166	Dupilumab (with or without TCS), n = 5352	Total, N = 6518
IGAxBSA vs. EASI
Kappa	0·71	0·74	0·74
Alpha’s standard error	0·0053	0·0037	0·0030
Kappa 95% upper limit	0·73	0·75	0·74
Kappa 95% lower limit	0·70	0·73	0·73
IGAxBSA vs. SCORAD
Kappa	0·55	0·60	0·59
Alpha’s standard error	0·0063	0·0043	0·0035
Kappa 95% upper limit	0·56	0·61	0·60
Kappa 95% lower limit	0·54	0·59	0·59

BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; SCORAD, Scoring Atopic Dermatitis; TCS, topical corticosteroids. ^aEASI threshold values are mild ≤ 7, moderate 7–21, severe ≥ 21. Disease severity strata for IGAxBSA are mild 0–30, moderate 30·1–130, severe 130·1–400. SCORAD threshold values are mild < 25, moderate 25–50, severe > 50.